Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

KROS

Keros Therapeutics (KROS)

Keros Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:KROS
FechaHoraFuenteTítuloSímboloCompañía
17/06/202405:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
17/06/202405:00GlobeNewswire Inc.Keros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology AssociationNASDAQ:KROSKeros Therapeutics Inc
04/06/202407:00GlobeNewswire Inc.Keros Therapeutics to Host a Corporate Update Conference Call and WebcastNASDAQ:KROSKeros Therapeutics Inc
03/06/202415:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KROSKeros Therapeutics Inc
03/06/202407:00GlobeNewswire Inc.Keros Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:KROSKeros Therapeutics Inc
28/05/202415:01GlobeNewswire Inc.Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of DirectorsNASDAQ:KROSKeros Therapeutics Inc
14/05/202409:00GlobeNewswire Inc.Keros Therapeutics to Present at the 29th Annual Congress of the European Hematology AssociationNASDAQ:KROSKeros Therapeutics Inc
08/05/202407:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KROSKeros Therapeutics Inc
08/05/202407:00GlobeNewswire Inc.Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial ResultsNASDAQ:KROSKeros Therapeutics Inc
14/03/202407:00GlobeNewswire Inc.Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic SyndromesNASDAQ:KROSKeros Therapeutics Inc
05/03/202407:00GlobeNewswire Inc.Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma ConferenceNASDAQ:KROSKeros Therapeutics Inc
28/02/202415:01GlobeNewswire Inc.Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:KROSKeros Therapeutics Inc
29/01/202407:00GlobeNewswire Inc.Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual CongressNASDAQ:KROSKeros Therapeutics Inc
09/01/202407:00GlobeNewswire Inc.Keros Therapeutics Announces Closing of Upsized Public Offering of Common StockNASDAQ:KROSKeros Therapeutics Inc
04/01/202415:04Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KROSKeros Therapeutics Inc
04/01/202415:02Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:KROSKeros Therapeutics Inc
03/01/202420:29GlobeNewswire Inc.Keros Therapeutics Announces Pricing of Upsized Public Offering of Common StockNASDAQ:KROSKeros Therapeutics Inc
03/01/202415:05GlobeNewswire Inc.Keros Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:KROSKeros Therapeutics Inc
11/12/202305:00GlobeNewswire Inc.Keros Therapeutics Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and ExpositionNASDAQ:KROSKeros Therapeutics Inc
07/11/202307:00GlobeNewswire Inc.Keros Therapeutics to Present at Upcoming Healthcare ConferencesNASDAQ:KROSKeros Therapeutics Inc
06/11/202307:00GlobeNewswire Inc.Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2023 Financial ResultsNASDAQ:KROSKeros Therapeutics Inc
02/11/202308:00GlobeNewswire Inc.Keros Therapeutics to Present at the 65th American Society of Hematology Annual Meeting and ExpositionNASDAQ:KROSKeros Therapeutics Inc
04/10/202307:00GlobeNewswire Inc.Keros Therapeutics Presents Preclinical Data from its KER-065 Program at the 28th International Annual Congress of the World Muscle SocietyNASDAQ:KROSKeros Therapeutics Inc
07/08/202307:00GlobeNewswire Inc.Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial ResultsNASDAQ:KROSKeros Therapeutics Inc
27/07/202315:01GlobeNewswire Inc.Corrected: Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial HypertensionNASDAQ:KROSKeros Therapeutics Inc
24/07/202307:00GlobeNewswire Inc.Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial HypertensionNASDAQ:KROSKeros Therapeutics Inc
12/06/202316:33Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:KROSKeros Therapeutics Inc
12/06/202315:14Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:KROSKeros Therapeutics Inc
12/06/202307:00GlobeNewswire Inc.Keros Therapeutics Announces Update to Participation at the Goldman Sachs 44th Annual Global Healthcare ConferenceNASDAQ:KROSKeros Therapeutics Inc
09/06/202305:04Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:KROSKeros Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:KROS

Su Consulta Reciente

Delayed Upgrade Clock